SUTRO BIOPHARMA, INC. (STRO) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -180.55M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-180.55M | (m) |
| 2026-03-31 | (m) | $-153.52M | (m) |
| 2025-12-31 | (m) | $-191.09M | (m) |
| 2025-09-30 | (m) | $-216.77M | (m) |
| 2025-06-30 | (m) | $-208.70M | (m) |
| 2025-03-31 | (m) | $-245.22M | (m) |
| 2024-12-31 | (m) | $-227.46M | (m) |
| 2024-09-30 | (m) | $-123.95M | (m) |
| 2024-06-30 | (m) | $-124.45M | (m) |
| 2024-03-31 | (m) | $-114.96M | (m) |
| 2023-12-31 | (m) | $-106.79M | (m) |
| 2023-09-30 | (m) | $-172.45M | (m) |
| 2023-06-30 | (m) | $-142.66M | (m) |
| 2023-03-31 | (m) | $-130.14M | (m) |
| 2022-12-31 | (m) | $-119.20M | (m) |
| 2022-09-30 | (m) | $-122.73M | (m) |
| 2022-06-30 | (m) | $-134.15M | (m) |
| 2022-03-31 | (m) | $-114.29M | (m) |
| 2021-12-31 | (m) | $-105.54M | (m) |
| 2021-09-30 | (m) | $-126.96M | (m) |
| 2021-06-30 | (m) | $-78.92M | (m) |
| 2021-03-31 | (m) | $-42.89M | (m) |
| 2020-12-31 | (m) | $-32.13M | (m) |
| 2020-09-30 | (m) | $12.63M | (m) |
| 2020-06-30 | (m) | $-17.42M | (m) |
| 2020-03-31 | (m) | $-61.09M | (m) |
| 2019-12-31 | (m) | $-55.74M | (m) |
| 2019-09-30 | (m) | $-42.45M | (m) |
| 2019-06-30 | (m) | $-39.77M | (m) |
| 2019-03-31 | (m) | $-37.52M | (m) |
| 2018-12-31 | (m) | $-35.32M | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | $-40.35M | (m) |
| 2018-03-31 | (m) | $-30.62M | (m) |
| 2017-12-31 | (m) | $-19.69M | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.70M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |